Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies

Laboratory Animal Science

Volumn 46, Issue 1, 1996, Pages 8-14

  Peterson, Norman C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY STRUCTURE; HUMAN; HYBRIDOMA; MOUSE; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0029878036     PISSN: 00236764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Drebin, J. A., V. C. Link, D. F. Stern, et al. 1985. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706.
2. Rodeck, IL, M. Herlyn, D. Herlyn, et al. 1987. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated effector cell-independent effects. Cancer Res. 47:3692-3696.
3. Fan, Z., H. Masui, I. Atlas, et al. 1993. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53:4322-4328.
4. Drebin, J. A., V. C. Link, and M. I. Greene, 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2:387-394.
5. Dillman, R. O. 1989. Monoclonal antibodies for treating cancer. Ann. Intern. Med. 111:592-603.
6. Kuzel, T. M., J. N. Winter, S. T. Rosen, et al. 1990. Monoclonal antibody therapy of lymphoproliferative disorders. Oncology (Huntingt) 4:77-84.
7. Shawler, D. L., R. M. Bartholomew, L. M. Smith, et al. 1985. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135:1530-1535.
8. Schroff, R. W., K. A. Foon, S. M. Beatty, et al. 1985. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45:879-885.
9. Isaacs, J. D. 1990. The antiglobulin response to therapeutic antibodies. Semin. Immunol. 2:449-456.
10. Levy, R., and R. A. Miller. 1983. Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Ann. Intern. Med. 14:1352-1359.
11. Jain, R. 1989. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:570-576.
12. Adair, J. 1992. Engineering antibodies for therapy. Immunol. Rev. 130:5-40.
13. Johnson, S., and R. E. Bird. 1991. Construction of single-chain Fv derivatives of monoclonal antibodies and their production in Escherichia coli. Methods Enzymol. 203:88-98.
14. Yokota, T., D. E. Milenic, M. Whitlow, et al. 1992. Rapid tumor penetration of single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:3402-3408.
15. Colcher, D., R. Bird, M. Roselli, et al. 1990. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 82:1191-1197.
16. Riechmann, L., M. Clark, H. Waldmann, et al. 1988. Reshaping human antibodies for therapy. Nature 332:323-327.
17. Ward, E. S., D. Gussow, A. D. Griffiths, et al. 1989. Binding activities of a repertoire of single immunoglobin variable domains secreted from Escherichia coli. Nature 341:544-546.
18. Wu, T. E., and E. Rabat. 1970. An analysis of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody diversity. J. Exp. Med. 132:211.
19. Chothia, C., A. M. Lesk, A. Tramontano, et al. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342:877-883.
20. Kabat, E., T. E. Wu, H. Perry, et al. 1991. Sequences of proteins of immunological interest. Public Health Service, National Institutes of Health publication no. 91-3242.
21. Porter, R. R. 1959. The hydrolysis of rabbit gamma-globulin and antibodies with crystalline papain. Biochem. J. 73:119.
22. Orlandi, R., D. H. Gussow, P. T. Jones, et al. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86:3833-3837.
23. Huse, W., and R. Lerner. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275-1281.
24. Pluckthun, A., and A. Skerra. 1989. Expression of functional antibody Fv and Fab fragments in Escherichia coli. Methods Enzymol. 178:497-515.
25. Ward, E. S. 1993. Antibody engineering using Escherichia coli as host. Adv. Pharmacol. 24:1-20.
26. Ayala, M., M. Duenas, A. Santos, et al. 1992. Bacterial single-chain antibody fragments, specific for carcinoembryonic antigen. Biotechniques 13:790-799.
27. Duenas, M., J. Vazques, M. Ayala, et al. 1994. Intra- and extracellular expression of an scFv antibody fragment in E. coli: effect of bacterial strains and pathway engineering using GroES/L chaperonins. BioTechniques 16:476-483.
28. Bird, R. 1988. Single-chain antigen-binding proteins. Science 242:423-426.
29. Wels, W., I. M. Harwerth, N. E. Hynes, et al. 1992. Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor. J. Steroid Biochem. Mol. Biol. 43(1-3):1-7.
30. Milenic, D. 1991. Construction, binding properties, metabolism, and tumor targeting of a single chain Fv derived from pancarcinoma monoclonal antibody CC49. Cancer Res. 51:6353-6371.
31. Huston, J. 1993. Medical applications of single chain antibodies. Int. Rev. Immunol. 10:195-217.
32. Gill, G. N., T. Kawamoto, C. Cochet, et al. 1984. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259:7755-7760.
33. Wels, W., I. M. Harwerth, M. Mueller, et al. 1992. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52:6310-6317.
34. Chaudhary, V. 1990. A rapid method of cloning functional variable region antibody genes in Escherichia coli as single chain immunotoxins. Proc. Natl. Acad. Sci. USA 87:1066-1070.
35. Trail, P., D. Willner, S. Lasch, et al. 1993. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-215.
36. Hoogenboom, H. R., G. Volckaert, and J. C. Raus. 1991. Construction and expression of antibody-tumor necrosis factor fusion proteins. Mol. Immunol. 28:1027-1037.
37. Nishimura, T., Y. Nakamura, H. Tsukamoto, et al. 1992. Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. Int. J. Cancer 50:800-804.
38. Weiner, L. M., M. Holmes, G. P. Adams, et al. 1993. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB2 and CD16. Cancer Res. 53:94-100.
39. Shalaby, M. R., M. Shepard, L. Presta, et al. 1992. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175:217-225.
40. Gasparini, G., W. J. Gullick, P. Bevilacqua, et al. 1992. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J. Clin. Oncol. 10:686-695.
41. Kabat, E. A., and T. T. Wu. 1991. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. J. Immunol. 147:1709-1719.
42. Wilson, I. A., and R. L. Stanfield. 1993. Antibody-antigen interactions. Curr. Opin. Struct. Biol. 3:113-118.
43. Saragovi, U., D. Fitzpatrick, A. Raktabuhr, et al. 1991. Design and synthesis of a mimetic of an antibody complementarity determining region. Science 253:792-795.
44. Williams, W. V., T. Kieber-Emmons, J. VonFeldt, et al. 1991. Design of bioactive peptides based on antibody hypervariable region structures. J. Biol. Chem. 266:5182-5190.
45. LoBuglio, A., R. Wheeler, J. Trang. 1989. Mouse/Human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86:4220-4224.
46. Billetta, L. 1993. Chimeric antibodies. Int. Rev. Immunol. 10:165-176.
47. Meredith, R. F., A. F. Lobuglio, W. E. Plott, et al. 1991. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J. Nucl. Med. 32:1162-1168.
48. Kang, H., K. Hidetoshi, M. Nakashima, et al. 1990. Mousehuman chimeric monoclonal antibody to carcinoembryonic antigen (CEA): in vitro and in vivo activities. Hybridoma 9:43-55.
49. Stevenson, F. K., A. J. Bell, R. Cusak, et al. 1991. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77:1071-1079.
50. Winter, G., and C. Milstein. 1991. Man-made antibodies. Nature 349:293-299.
51. Co, M. S., and C. Queen. 1991. Humanized antibodies for therapy. Nature 351:501-502.
52. Verhoeyen, M., C. Milstein, and G. Winter. 1988. Reshaping human antibodies: grafting an antilysozyme activity. Science 239:1534-1536.
53. Gorman, S. D., M. R. Clark, E. G. Routledge, et al. 1991. Reshaping a therapeutic CD4 antibody. Proc. Natl. Acad. Sci. USA 88:4181-4185.
54. Hale, G., M. J. S. Dyer, M. R. Clark, et al. 1988 Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody compath-1H. Lancet 2(8625):1394-1399.
55. Carter, P., L. Presta, C. M. Gorman, et al. 1992. Humanization of an anti-p185/HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285-4289.
56. Junghans, R. P., T. A. Waldmann, N. F. Landolfi, et al. 1990. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50:1495-1502.
57. Wright, A., S. U. Shin, and S. L. Morrison. 1992. Genetically engineered antibodies: progress and prospects. Grit. Rev. Immunol. 12:125-168.
58. Choi, T. K., P. W. Hollenbach, B. E. Pearson, et al. 1993. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome. Nat. Genet. 4:117-123.
59. Taki, S., M. Meiering, and K. Rajewsky. 1993. Targeted insertion of a variable region gene into the immunoglobulin heavy chain locus. Science 262:1268-1274.
60. Bruggemann, M., C. Spicer, L. Buluwela, et al. 1991. Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. Eur. J. Immunol. 21:1323-1326.
61. Wagner, S. D., G. T. Williams, T. Larson, et al. 1994. Antibodies generated from human immunoglobulin miniloci in transgenic mice. Nucleic Acids Res 22:1389-1393.
62. Marks, J. D., H. R. Hoogenboom, and G. Winter. 1992. Molecular evolution of proteins on filamentous phage. J. Biol. Chem. 267:16007-16010.
63. Huse, W. D., L. Sastry, S. A. Iverson, et al. 1992. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Biotechnology 24:517-523,
64. Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, et al. 1991. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-597.
65. Barbas, C. F., and R. A. Lerner. 1991. Combinatorial immunoglobulin libraries on the surface of phage (Phabs): rapid selection of antigen specific Fabs. Methods 2:119-124.
66. Nissim, A., H. Hoogenboom, I. M. Tomlinson, et al. 1994. Antibody fragments from a "single pot" phage display library as immunochemical reagents. EMBO J. 13:692-398.
67. Persson, M. A. A. 1993. Combinatorial libraries. Intern. Rev. Immunol. 10:153-163.
68. Barbas, C. F., J. E. Crowe, D. Cababa, et al. 1992. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc. Natl. Acad. Sci. USA 89:10164-10168.
69. Gram, H., L. Marconi, C. Barbas, et al. 1992. Selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. In Vitro 89:3576-3580.